Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.

ABSTRACT:

Background

HER2-positive cancers involve amplification or overexpression of the HER2 gene, leading to aggressive tumor growth across several cancer types, including breast, gastric, ovarian, and pancreatic cancers. Detection methods such as immunohistochemistry, next-generation sequencing, and fluorescence in situ hybridization are used, with new advancements like biosensors and circulating tumor DNA offering improved diagnostic potential. Treatment strategies have evolved, including anti-HER2 drugs like trastuzumab and newer agents like zanidatamab, which show promise against HER2-positive malignancies.

Methods

A comprehensive search of the following academic databases was performed including PubMed, Cochrane Library, and clinicaltrials.gov. A detailed search string was mad

SUBMITTER: Kanwal W 

PROVIDER: S-EPMC11871714 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature